

## DRUG ALERT

### CLASS 2 MEDICINES RECALL

Action within 48 Hours

Pharmacy and Wholesaler Level Recall

Dear Healthcare Professional

**Kyowa Kirin Limited**

**PL 16508/0036**

**Xomolix 2.5 mg/ml solution for injection**

Batch Number	Expiry Date	Pack Size	First Distributed
1821A	07 2021	10 x 1ml ampoules	19 November 2019
1919	11 2022	10 x 1ml ampoules	15 May 2020

Active Pharmaceutical Ingredient: droperidol

#### **Brief description of the problem**

Kyowa Kirin Limited is recalling the above batches as a precautionary measure, due to the reports of glass and cellulose fibre contamination, which was identified during stability and reference sample inspection.

Particulate matter could potentially induce a local inflammatory response, such as injection site reactions, which include pain, irritation, erythema as well as potentially, a granulomatous nodule. In rare cases ulceration could potentially develop if the inflammation is intensive but it would usually be limited to the injection site or the surrounding area.

The possibility of occurrence of generalised hypersensitivity would depend on the nature of particulate matter and in case of glass particles, which can also carry metals utilised in glass manufacture, could be considered negligible. Droperidol is known to cause hypersensitivity reactions; anaphylactic reaction, angioneurotic oedema and hypersensitivity are listed as adverse drug reactions in the current



Summary of Product Characteristics. Following a review by Kyowa Kirin Limited of all hypersensitivity cases received, this did not detect any information indicative of the reported hypersensitivity reaction being caused by particulate matter.

Parenteral administration of particulates may potentially lead to embolization in small capillaries but such events have not been reported in association with these products since contamination was identified.

### **Advice for healthcare professionals**

Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Patients who have been recently administered a product from the affected batch should be monitored closely, where possible. Healthcare professionals are advised to report any side effects via the [MHRA Yellow Card Scheme](#)

General precautions should be considered as part of the handling for this product. As stated in the Summary of Product Characteristics, section 6.6 Special precautions for disposal and other handling, "*The solution should be inspected visually prior to use. Only clear and colourless solutions free from visible particles should be used.*"

### **Further Information**

For Stock control enquiries please contact  
Karen Murray, Commercial Manager

- Telephone: +44 (0) 1896 661665 / Mobile: +44 (0) 7712 001288
- E-mail: [karen.murray@kyowakirin.com](mailto:karen.murray@kyowakirin.com)

For Medical information enquiries please contact

- Medical Information Direct Line: + 44 (0)1896 664 000
- E-mail: [medinfo@kyowakirin.com](mailto:medinfo@kyowakirin.com)

For Quality information please contact  
Martin Smith (Responsible Person)

- Telephone: Mobile: +44 7904671807
- E-mail: [Martin.Smith@kyowakirin.com](mailto:Martin.Smith@kyowakirin.com)

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this notice.



RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

**TO ALL CHEMISTS, DOCTORS ON THE LISTS**

Pharmaceutical Services  
2 Franklin Street  
BELFAST  
BT2 8DQ

Telephone No. 028 9536 0333

**1<sup>st</sup> July 2021**

Pharmaceutical website: <http://www.hscbusiness.hscni.net>